Revolution Medicines (RVMD) closed at $186.99 on October 23, 2026, down 0.4% from the previous close, on volume of 1,209,511 shares (30-day average 2,169,399).
Data as of October 23, 2026.
23-Oct-2026
Globe Newswire (Fri, 23-Oct 7:30 AM ET)
UBS Remains a Buy on Revolution Medicines (RVMD)
TipRanks (Thu, 22-Oct 9:15 AM ET)
TipRanks (Thu, 22-Oct 8:50 AM ET)
Globe Newswire (Wed, 21-Oct 4:05 PM ET)
TD Cowen Remains a Buy on Revolution Medicines (RVMD)
TipRanks (Wed, 21-Oct 8:59 AM ET)
TipRanks (Wed, 21-Oct 7:56 AM ET)
Globe Newswire (Tue, 20-Oct 8:00 AM ET)
Globe Newswire (Thu, 15-Oct 9:45 AM ET)
Globe Newswire (Mon, 5-Oct 8:00 AM ET)
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
Revolution Medicines trades on the NASDAQ stock market under the symbol RVMD.
As of October 23, 2026, RVMD stock price declined to $186.99 with 1,209,511 million shares trading.
RVMD has a beta of 2.47, meaning it tends to be more sensitive to market movements. RVMD has a correlation of 0.19 to the broad based SPY ETF.
RVMD has a market cap of $40.08 billion. This is considered a Large Cap stock.
Last quarter Revolution Medicines reported $0 in Revenue and -$3.06 earnings per share. This fell short of revenue expectation by $-40 million and missed earnings estimates by -$1.05.
In the last 3 years, RVMD traded as high as $224.31 and as low as $18.00.
The top ETF exchange traded funds that RVMD belongs to (by Net Assets): VTI, VB, VBK, VXF, IBB.
RVMD has outperformed the market in the last year with a price return of +249.9% while the SPY ETF gained +14.3%. However, in the short term, RVMD had mixed performance relative to the market. It has underperformed in the last 3 months, returning -0.9% vs +3.2% return in SPY. But in the last 2 weeks, RVMD shares have fared better than the market returning -1.5% compared to SPY -2.4%.
RVMD support price is $181.37 and resistance is $194.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RVMD shares will trade within this expected range on the day.
